The Alexander Project:: the benefits from a decade of surveillance

被引:89
作者
Felmingham, D
White, AR
Jacobs, MR
Appelbaum, PC
Poupard, J
Miller, LA
Grüneberg, RN
机构
[1] GR Micro Ltd, London NW1 3ER, England
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
[3] GlaxoSmithKline Inc, Harlow, Essex, England
[4] Milton S Hershey Med Ctr, Hershey, PA USA
[5] GlaxoSmithKline Inc, Collegeville, PA USA
关键词
Streptococcus pneumoniae; Haemophilus influenzae; Moraxella catarrhalis; antimicrobial resistance; antimicrobial consumption and appropriate use; pharmacokinetics/pharmacodynamics; susceptibility breakpoints;
D O I
10.1093/jac/dki297
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The Alexander Project, initiated in 1992 as an international, multicentre, longitudinal surveillance study of antimicrobial susceptibility among common respiratory pathogens, has been pivotal in defining the role of global surveillance. At the time, there were few studies in which data were collected in a way that allowed meaningful comparisons to be made between studies, locations or overtime. The project instituted the use of a central laboratory and standardized methods for the collection of isolates and determination of susceptibility, and this was continued with the addition of two further reference laboratories. Data from the study have provided a resource for measuring trends in the susceptibility patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis at country, regional and global levels. Determination and publication of quantitative MICs enabled detailed assessment of changes in susceptibility distributions and assessment of microbiological and potential clinical susceptibility using different breakpoints, including those based on pharmacokinetic/pharmacodynamic parameters. Comparisons of antimicrobial usage patterns and resistance prevalences over time allowed hypotheses to be examined with respect to the role of quantity and type of antimicrobial use in the selection and spread of resistance. The resulting collection of isolates has provided a valuable resource for molecular studies into the evolution of resistance over time and location; a substantial proportion of this collection is now in the public domain. This paper reviews the 10 years of the Alexander Project and the benefits it has brought to an understanding of the evolution of antibacterial resistance in community respiratory bacteria.
引用
收藏
页码:3 / 21
页数:19
相关论文
共 85 条
[1]
Resistance patterns of Haemophilus influenzae [J].
Acar, JF .
JOURNAL OF CHEMOTHERAPY, 1999, 11 :44-50
[2]
In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae:: Application to breakpoint determinations [J].
Andes, D ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2375-2379
[3]
Antimicrobial treatment guidelines for acute bacterial rhinosinusitis - Executive summary [J].
Anon, JB ;
Jacobs, MR ;
Roche, R ;
Poole, MD ;
Merck, D ;
Ambrose, PG ;
Benninger, MS ;
Hadley, JA ;
Craig, WA ;
Andes, DR ;
Bernstein, JM ;
Besser, RE ;
Dowell, SF ;
Drusano, GL ;
Klepser, ME ;
Nicolau, D ;
Radowsky, A ;
Reller, LB ;
Wald, ER ;
Zucker, DR .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2004, 130 (01) :1-45
[4]
Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence [J].
Ball, P ;
Baquero, F ;
Cars, O ;
File, T ;
Garau, J ;
Klugman, K ;
Low, DE ;
Rubinstein, E ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) :31-40
[5]
Evolving resistance patterns of Streptococcus pneumoniae:: A link with long-acting macrolide consumption? [J].
Baquero, F .
JOURNAL OF CHEMOTHERAPY, 1999, 11 :35-43
[7]
Surveillance of antimicrobial resistance - what, how and whither? [J].
Bax, R ;
Bywater, R ;
Cornaglia, G ;
Goossens, H ;
Hunter, P ;
Isham, V ;
Jarlier, V ;
Jones, R ;
Phillips, I ;
Sahm, D ;
Senn, S ;
Struelens, M ;
Taylor, D ;
White, A .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (06) :316-325
[9]
RANDOMIZED STUDY OF CARBENICILLIN PLUS CEFAMANDOLE OR TOBRAMYCIN IN THE TREATMENT OF FEBRILE EPISODES IN CANCER-PATIENTS [J].
BODEY, GP ;
KETCHEL, SJ ;
RODRIGUEZ, V .
AMERICAN JOURNAL OF MEDICINE, 1979, 67 (04) :608-616
[10]
Bozdogan Bulent, 2004, Current Drug Targets - Infectious Disorders, V4, P169, DOI 10.2174/1568005043340821